Original story from Bicycle Therapeutics (Cambridge, UK). Execution of a 15-year contract, including an option to renew with UK Nuclear Decommissioning Authority (Cumbria, UK) for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of doses of 212Pb every year. Partnership with the United Kingdom National Nuclear Laboratory (UKNNL; London, UK) to scale up the extraction of 228Th from RepU for onward processing into a 212Pb generator. Agreement with SpectronRx to develop a bespoke wholly owned 212Pb generator, with initial quantities of 212Pb successfully produced. CAMBRIDGE, England & BOSTON, December 16, 2025 – Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU). RepU continually regenerates, providing a potentially sustainable supply of 212Pb. Bicycle intends to utilize the RepU provided by this agreement in its development of potential lifesaving therapies. In addition, Bicycle announced a collaboration with United Kingdom National Nuclear Laboratory (UKNNL), pursuant to which it plans to extract 228Th from the RepU obtained from NDA. The extracted 228Th will then be further processed into 224Ra and loaded into a bespoke 212Pb generator being developed exclusively for Bicycle by SpectronRx. 212Pb is a radioisotope and one of the more potent therapeutic payloads against cancer…
